erlotinib13c6

Erlotinib-13C6 (CP-358774-13C6) is a 13C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR[1]. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer[1].Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process[2]. [1]. Moyer JD, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997, 57(21), 4838-4848.[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

Erlotinib-13C6 HCl 是 Erlotinib HCl 的 13C 的化合物。Erlotinib HCl 的 CAS 号为 183321-74-6。Erlotinib 是一种直接作用的EGFR酪氨酸激酶抑制剂，用于治疗非小细胞肺癌，对人 EGFR 的IC50为 2 nM。它可降低完整肿瘤细胞的 EGFR 自磷酸化，IC50为 20 nM。